PubRank

Ronald J Bosch

Author PubWeight™ 169.80‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med 2009 19.90
2 Predictive value of plasma HIV RNA level on rate of CD4 T-cell decline in untreated HIV infection. JAMA 2006 7.14
3 Depletion of latent HIV-1 infection in vivo: a proof-of-concept study. Lancet 2005 5.75
4 The prevalence and incidence of neurocognitive impairment in the HAART era. AIDS 2007 5.18
5 Sex differences in the Toll-like receptor-mediated response of plasmacytoid dendritic cells to HIV-1. Nat Med 2009 4.22
6 Comparative analysis of measures of viral reservoirs in HIV-1 eradication studies. PLoS Pathog 2013 4.05
7 Late presentation for human immunodeficiency virus care in the United States and Canada. Clin Infect Dis 2010 3.72
8 Cohort profile: the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD). Int J Epidemiol 2007 3.46
9 The effect of raltegravir intensification on low-level residual viremia in HIV-infected patients on antiretroviral therapy: a randomized controlled trial. PLoS Med 2010 3.24
10 Coaxing HIV-1 from resting CD4 T cells: histone deacetylase inhibition allows latent viral expression. AIDS 2004 3.17
11 Valproic acid without intensified antiviral therapy has limited impact on persistent HIV infection of resting CD4+ T cells. AIDS 2008 2.87
12 Invasive cervical cancer risk among HIV-infected women: a North American multicohort collaboration prospective study. J Acquir Immune Defic Syndr 2013 2.78
13 A trial of the effect of micronutrient supplementation on treatment outcome, T cell counts, morbidity, and mortality in adults with pulmonary tuberculosis. J Infect Dis 2008 2.77
14 Sensitivity analysis for the assessment of causal vaccine effects on viral load in HIV vaccine trials. Biometrics 2003 2.76
15 Risk of anal cancer in HIV-infected and HIV-uninfected individuals in North America. Clin Infect Dis 2012 2.50
16 Immediate antiviral therapy appears to restrict resting CD4+ cell HIV-1 infection without accelerating the decay of latent infection. Proc Natl Acad Sci U S A 2012 2.27
17 Antiretroviral intensification and valproic acid lack sustained effect on residual HIV-1 viremia or resting CD4+ cell infection. PLoS One 2010 2.09
18 Trends in multidrug treatment failure and subsequent mortality among antiretroviral therapy-experienced patients with HIV infection in North America. Clin Infect Dis 2009 2.05
19 Limited immune restoration after 3 years' suppression of HIV-1 replication in patients with moderately advanced disease. AIDS 2002 2.02
20 AIDS clinical trials group longitudinal linked randomized trials (ALLRT): rationale, design, and baseline characteristics. HIV Clin Trials 2008 1.99
21 Effects of central nervous system antiretroviral penetration on cognitive functioning in the ALLRT cohort. AIDS 2011 1.90
22 Association between systemic inflammation and incident diabetes in HIV-infected patients after initiation of antiretroviral therapy. Diabetes Care 2010 1.86
23 Polyamides reveal a role for repression in latency within resting T cells of HIV-infected donors. J Infect Dis 2004 1.64
24 Long-term increase in CD4+ T-cell counts during combination antiretroviral therapy for HIV-1 infection. AIDS 2010 1.54
25 Peripheral neuropathy in HIV: prevalence and risk factors. AIDS 2011 1.53
26 Genetic correlates of efavirenz hypersusceptibility. AIDS 2004 1.50
27 Suppression of HIV-1 replication by antiretroviral therapy improves renal function in persons with low CD4 cell counts and chronic kidney disease. AIDS 2008 1.46
28 No evidence for decay of the latent reservoir in HIV-1-infected patients receiving intensive enfuvirtide-containing antiretroviral therapy. J Infect Dis 2010 1.45
29 No effect of raltegravir intensification on viral replication markers in the blood of HIV-1-infected patients receiving antiretroviral therapy. J Acquir Immune Defic Syndr 2012 1.39
30 Antiretroviral therapy in acute and recent HIV infection: a prospective multicenter stratified trial of intentionally interrupted treatment. AIDS 2009 1.35
31 No risk of myocardial infarction associated with initial antiretroviral treatment containing abacavir: short and long-term results from ACTG A5001/ALLRT. Clin Infect Dis 2011 1.32
32 A randomized, partially blinded phase 2 trial of antiretroviral therapy, HIV-specific immunizations, and interleukin-2 cycles to promote efficient control of viral replication (ACTG A5024). J Infect Dis 2006 1.27
33 The size of the expressed HIV reservoir predicts timing of viral rebound after treatment interruption. AIDS 2016 1.25
34 Safety and immunogenicity of therapeutic DNA vaccination in individuals treated with antiretroviral therapy during acute/early HIV-1 infection. PLoS One 2010 1.21
35 Immunophenotypic markers and antiretroviral therapy (IMART): T cell activation and maturation help predict treatment response. J Infect Dis 2004 1.21
36 A randomized therapeutic vaccine trial of canarypox-HIV-pulsed dendritic cells vs. canarypox-HIV alone in HIV-1-infected patients on antiretroviral therapy. Vaccine 2009 1.21
37 Maternal disease stage and child undernutrition in relation to mortality among children born to HIV-infected women in Tanzania. J Acquir Immune Defic Syndr 2007 1.20
38 Plasma apolipoprotein L1 levels do not correlate with CKD. J Am Soc Nephrol 2013 1.15
39 Iron deficiency and anemia predict mortality in patients with tuberculosis. J Nutr 2011 1.14
40 CD4 count at presentation for HIV care in the United States and Canada: are those over 50 years more likely to have a delayed presentation? AIDS Res Ther 2010 1.13
41 Detection of drug-resistant minority variants of HIV-1 during virologic failure of indinavir, lamivudine, and zidovudine. J Infect Dis 2004 1.12
42 Risk factors for tuberculosis after highly active antiretroviral therapy initiation in the United States and Canada: implications for tuberculosis screening. J Infect Dis 2011 1.11
43 Immune reconstitution and predictors of virologic failure in adolescents infected through risk behaviors and initiating HAART: week 60 results from the PACTG 381 cohort. AIDS Res Hum Retroviruses 2006 1.11
44 Weighted phenotypic susceptibility scores are predictive of the HIV-1 RNA response in protease inhibitor-experienced HIV-1-infected subjects. J Infect Dis 2004 1.10
45 Factors associated with mortality in HIV-infected and uninfected patients with pulmonary tuberculosis. BMC Public Health 2009 1.10
46 Cytomegalovirus-specific immunity and protection against viremia and disease in HIV-infected patients in the era of highly active antiretroviral therapy. J Infect Dis 2006 1.09
47 Interleukin-7 induces HIV type 1 outgrowth from peripheral resting CD4+ T cells. J Acquir Immune Defic Syndr 2004 1.05
48 Vitamin supplementation of HIV-infected women improves postnatal child growth. Am J Clin Nutr 2005 1.04
49 Reverse transcriptase mutations 118I, 208Y, and 215Y cause HIV-1 hypersusceptibility to non-nucleoside reverse transcriptase inhibitors. AIDS 2006 1.04
50 Incident hepatitis C virus infection among US HIV-infected men enrolled in clinical trials. Clin Infect Dis 2011 1.04
51 Multiple micronutrient supplementation in Tanzanian infants born to HIV-infected mothers: a randomized, double-blind, placebo-controlled clinical trial. Am J Clin Nutr 2012 1.03
52 Long-term changes in circulating CD4 T lymphocytes in virologically suppressed patients after 6 years of highly active antiretroviral therapy. AIDS 2004 1.03
53 The effects of HIV type-1 viral suppression and non-viral factors on quantitative proteinuria in the highly active antiretroviral therapy era. Antivir Ther 2009 1.02
54 MDR1 gene polymorphisms and phase 1 viral decay during HIV-1 infection: an adult AIDS Clinical Trials Group study. J Acquir Immune Defic Syndr 2003 1.01
55 Distinct mechanisms of T cell reconstitution can be identified by estimating thymic volume in adult HIV-1 disease. J Infect Dis 2005 1.00
56 Sevelamer does not decrease lipopolysaccharide or soluble CD14 levels but decreases soluble tissue factor, low-density lipoprotein (LDL) cholesterol, and oxidized LDL cholesterol levels in individuals with untreated HIV infection. J Infect Dis 2014 1.00
57 Phenotypic susceptibility and virological outcome in nucleoside-experienced patients receiving three or four antiretroviral drugs. AIDS 2003 0.98
58 The impact of age on the prognostic capacity of CD8+ T-cell activation during suppressive antiretroviral therapy. AIDS 2013 0.97
59 Association of T cell proliferative responses and phenotype with virus control in chronic progressive HIV-1 disease. J Infect Dis 2004 0.97
60 Iron status predicts treatment failure and mortality in tuberculosis patients: a prospective cohort study from Dar es Salaam, Tanzania. PLoS One 2012 0.96
61 Early patterns of adherence in adolescents initiating highly active antiretroviral therapy predict long-term adherence, virologic, and immunologic control. AIDS Patient Care STDS 2009 0.96
62 Higher expression of several interferon-stimulated genes in HIV-1-infected females after adjusting for the level of viral replication. J Infect Dis 2013 0.96
63 HIV-1 amino acid changes among participants with virologic failure: associations with first-line efavirenz or atazanavir plus ritonavir and disease status. J Infect Dis 2012 0.96
64 Measurement of naive CD4 cells reliably predicts potential for immune reconstitution in HIV. J Acquir Immune Defic Syndr 2010 0.94
65 Vitamin B-12 supplementation during pregnancy and early lactation increases maternal, breast milk, and infant measures of vitamin B-12 status. J Nutr 2014 0.94
66 Intracellular Casp8p41 content is inversely associated with CD4 T cell count. J Infect Dis 2010 0.93
67 Immune Activation While on Potent Antiretroviral Therapy Can Predict Subsequent CD4+ T-Cell Increases Through 15 Years of Treatment. HIV Clin Trials 2013 0.91
68 Performance characteristics of the Cavidi ExaVir viral load assay and the ultra-sensitive P24 assay relative to the Roche Monitor HIV-1 RNA assay. J Clin Virol 2010 0.90
69 Predictors of residual viraemia in patients on long-term suppressive antiretroviral therapy. Antivir Ther 2012 0.90
70 Body mass index and CD4+ T-lymphocyte recovery in HIV-infected men with viral suppression on antiretroviral therapy. HIV Clin Trials 2011 0.89
71 CD8+ T-cell activation in HIV-1-infected patients experiencing transient low-level viremia during antiretroviral therapy. J Acquir Immune Defic Syndr 2013 0.89
72 A study of the immunology, virology, and safety of prednisone in HIV-1-infected subjects with CD4 cell counts of 200 to 700 mm(-3). J Acquir Immune Defic Syndr 2003 0.89
73 Vitamin D status and TB treatment outcomes in adult patients in Tanzania: a cohort study. BMJ Open 2013 0.88
74 HIV infection and the incidence of malaria among HIV-exposed children from Tanzania. J Infect Dis 2012 0.88
75 Relationship between CD4+ T-cell counts/HIV-1 RNA plasma viral load and AIDS-defining events among persons followed in the ACTG longitudinal linked randomized trials study. J Acquir Immune Defic Syndr 2010 0.88
76 Activity, safety, and immunological effects of hydroxyurea added to didanosine in antiretroviral-naive and experienced HIV type 1-infected subjects: a randomized, placebo-controlled trial, ACTG 307. AIDS Res Hum Retroviruses 2004 0.88
77 The development and utility of a clinical algorithm to predict early HIV-1 infection. J Acquir Immune Defic Syndr 2005 0.87
78 Detection of replication-competent human immunodeficiency virus type 1 (HIV-1) in cultures from patients with levels of HIV-1 RNA in plasma suppressed to less than 500 or 50 copies per milliliter. J Clin Microbiol 2002 0.87
79 HIV peripheral neuropathy progression: protection with glucose-lowering drugs? J Neurovirol 2012 0.86
80 Clinical impact of the M184V mutation on switching to didanosine or maintaining lamivudine treatment in nucleoside reverse-transcriptase inhibitor-experienced patients. J Infect Dis 2003 0.85
81 Effect of vitamin supplements on HIV shedding in breast milk. Am J Clin Nutr 2010 0.85
82 Predictors and consequences of anaemia among antiretroviral-naïve HIV-infected and HIV-uninfected children in Tanzania. Public Health Nutr 2009 0.85
83 A randomized trial of multivitamin supplementation in children with tuberculosis in Tanzania. Nutr J 2011 0.84
84 Residual plasma viraemia and infectious HIV-1 recovery from resting memory CD4 cells in patients on antiretroviral therapy: results from ACTG A5173. Antivir Ther 2013 0.83
85 Factors associated with CD8+ T-cell activation in HIV-1-infected patients on long-term antiretroviral therapy. J Acquir Immune Defic Syndr 2014 0.82
86 Vitamin A and vitamin B-12 concentrations in relation to mortality and morbidity among children born to HIV-infected women. J Trop Pediatr 2009 0.82
87 Multivitamin supplements have no effect on growth of Tanzanian children born to HIV-infected mothers. J Nutr 2013 0.82
88 Peripheral neuropathy in ART-experienced patients: prevalence and risk factors. J Neurovirol 2013 0.81
89 Nonnucleoside reverse transcriptase inhibitor phenotypic hypersusceptibility can be demonstrated in different assays. J Acquir Immune Defic Syndr 2005 0.81
90 Effect of hydroxyurea and dideoxyinosine on intracellular 3'-deoxyadenosine-5'-triphosphate concentrations in HIV-infected patients. AIDS Res Hum Retroviruses 2007 0.81
91 Multivitamin supplementation improves haematologic status in children born to HIV-positive women in Tanzania. J Int AIDS Soc 2013 0.81
92 Safety and immunogenicity of a polyvalent peptide C4-V3 HIV vaccine in conjunction with IL-12. AIDS 2004 0.81
93 Brief Report: Relationship Among Viral Load Outcomes in HIV Treatment Interruption Trials. J Acquir Immune Defic Syndr 2016 0.80
94 Sex differences in the effects of maternal vitamin supplements on mortality and morbidity among children born to HIV-infected women in Tanzania. Br J Nutr 2010 0.80
95 Effect of adjunct hydroxyurea on helper T cell immunity in HIV type 1-infected patients with virological suppression. AIDS Res Hum Retroviruses 2004 0.80
96 Baseline immune phenotypes and CD4+ T lymphocyte responses to antiretroviral therapy in younger versus older HIV-infected individuals. J Clin Immunol 2011 0.80
97 Assessment of diagnostic markers by goodness-of-fit tests. Stat Med 2003 0.80
98 The effect of lamivudine therapy and M184V on the antiretroviral activity of didanosine. J Acquir Immune Defic Syndr 2007 0.80
99 Lower CD4 cell count and higher virus load, but not antiretroviral drug resistance, are associated with AIDS-defining events and mortality: an ACTG Longitudinal Linked Randomized Trials (ALLRT) analysis. HIV Clin Trials 2011 0.80
100 Statin therapy and changes in hip circumference among HIV-infected participants in the ALLRT Cohort. Antivir Ther 2009 0.78
101 Phylogenetic evidence of HIV-1 sequence evolution in subjects with persistent low-level viraemia. Antivir Ther 2014 0.78
102 More reasons to reexamine the definition of viral blip during antiretroviral therapy. J Infect Dis 2012 0.78
103 Drug-resistant virus has reduced ability to induce immune activation. J Acquir Immune Defic Syndr 2012 0.76
104 Augmented HIV-specific interferon-gamma responses, but impaired lymphoproliferation during interruption of antiretroviral treatment initiated in primary HIV infection. J Acquir Immune Defic Syndr 2011 0.76
105 Prevalence of primary resistance at baseline in acutely and recently infected subjects enrolled in AIDS clinical trials group protocol 371. J Acquir Immune Defic Syndr 2010 0.75
106 Factors associated with remaining on initial randomized efavirenz-containing regimens. AIDS 2013 0.75
107 Innovations in nutrition education and global health: the Bangalore Boston nutrition collaborative. BMC Med Educ 2014 0.75
108 Patterns of peripheral neuropathy in ART-naïve patients initiating modern ART regimen. J Neurovirol 2015 0.75
109 A Flow-Based Model of the HIV Care Continuum in the United States. J Acquir Immune Defic Syndr 2017 0.75
110 Associations of CD4+ T-cell count, HIV-1 RNA viral load, and antiretroviral therapy with Kaposi sarcoma risk among HIV-infected persons in the United States and Canada. J Acquir Immune Defic Syndr 2017 0.75
111 Impact of aging on neurocognitive performance in previously antiretroviral-naïve HIV+ individuals on their first suppressive regimen. AIDS 2017 0.75
112 A reporting tool for real-time assessment of study data availability. Clin Trials 2004 0.75
113 Profile-likelihood inference for highly accurate diagnostic tests. Biometrics 2002 0.75